- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02894398
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (INGE-B)
Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open-label, multi-center, single arm, non-comparative phase II study in women with HR+/HER2- advanced breast cancer receiving palbociclib in addition to an aromatase inhibitor or fulvestrant. The study will take place in Germany (85 study centers).
In total, 360 patients will be enrolled in this study. 6 treatment groups are planned. The study seeks to recruit 60 (58-62) patients per recruitment group. For first-line treatment with palbociclib - and letrozole (Enrollment Group 1), anastrozole (Enrollment Group 2), exemestane (Enrollment Group 3) or fulvestrant (Enrollment Group 4) and 60 (58-62) patients for second- or later-line treatment with palbociclib -and letrozole (Enrollment Group 5) or fulvestrant (Enrollment Group 6). Recruitment will be centrally monitored to allow closure of a respective group as soon as 60 (58-62) patients have been enrolled.
Treatment will be continued until disease progression, intolerable toxicity, death or any other reason. In case a combination partner is discontinued, palbociclib has to be discontinued. In case treatment with palbociclib is stopped, combination partner can be continued according to investigator's discretion. Irrespectively of the combination partner, the discontinuation of palbociclib is defined as end of treatment (EOT) in this study. After EOT the patient enters the follow-up period.
Primary end point is clinical benefit rate 24 weeks after the first study treatment of the patient.
A study independent, decentral, "virtual" biobank will be established. All patients will be asked to give consent for their tumor samples to be used for future investigational research. Study sites will inform the local pathologists about the patient's consent and ask for the tissue sample to be reserved for future analyses. The site is requested to collect contact details of the pathologist storing the tumor sample, the sample's identification number(s), and to document these in the eCRF.
The decision to perform subsequent investigational research studies on collected samples will be based on outcome data from this study or from new scientific findings related to the drug class or disease, as well as reagent and assay availability.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany
- Research Site
-
Aschaffenburg, Germany
- Research Site
-
Augsburg, Germany
-
Baden-Baden, Germany
- Research Site
-
Berlin, Germany
- Research Site
-
Bochum, Germany
-
Bonn, Germany
-
Bottrop, Germany
- Research Site
-
Bremerhaven, Germany
-
Celle, Germany
- Research Site
-
Dessau, Germany
-
Donauwörth, Germany
- Research Site
-
Dortmund, Germany
- Research Site
-
Dresden, Germany
- Research Site
-
Essen, Germany
- Research Site
-
Esslingen, Germany
- Research Site
-
Frankfurt, Germany
- Research Site
-
Freiburg, Germany
- Research Site
-
Gerlingen, Germany
- Research Site
-
Goslar, Germany
-
Greifswald, Germany
-
Göttingen, Germany
-
Göttingen, Germany
- Research Site
-
Güstrow, Germany
-
Gütersloh, Germany
- Research Site
-
Halle, Germany
- Research Site
-
Hamburg, Germany
- Research Site
-
Homburg, Germany
-
Ilsede, Germany
-
Kaiserslautern, Germany
-
Karlsruhe, Germany
- Research Site
-
Kassel, Germany
- Research Site
-
Krefeld, Germany
- Research Site
-
Langen, Germany
- Research Site
-
Leer, Germany
- Research Site
-
Luneburg, Germany
-
Lörrach, Germany
-
Lübeck, Germany
-
Mannheim, Germany
-
Minden, Germany
-
Mönchengladbach, Germany
- Research Site
-
Mühlhausen, Germany
- Research Site
-
Mülheim, Germany
-
München, Germany
-
München, Germany
- Research Site
-
Münster, Germany
- Research Site
-
Neumünster, Germany
-
Neuruppin, Germany
-
Offenburg, Germany
-
Oldenburg, Germany
-
Passau, Germany
-
Potsdam, Germany
-
Recklinghausen, Germany
- Research Site
-
Regensburg, Germany
- Research Site
-
Rostock, Germany
-
Saarbrucken, Germany
-
Schorndorf, Germany
-
Singen, Germany
- Research Site
-
Speyer, Germany
-
Stade, Germany
-
Stolberg, Germany
-
Stuttgart, Germany
-
Traunstein, Germany
-
Ulm, Germany
- Research Site
-
Villingen-Schwenningen, Germany
-
Westerstede, Germany
-
Wilhelmshaven, Germany
- Research Site
-
Witten, Germany
-
Würselen, Germany
-
Würzburg, Germany
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Personally signed written informed consent prior to beginning protocol specific procedures, including expected cooperation of the patient for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
- Women with proven diagnosis of advanced, defined as locally advanced inoperable or metastatic, adenocarcinoma of the breast
- Hormone-receptor-positive (HR+) disease, defined as estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PgR+)
- Human epidermal growth factor receptor 2-negative (HER2-) disease (HER2 neg/+ or HER2++ with CISH/FISH neg.)
- Pre-/perimenopausal women receiving concomitant therapy with an luteinizing hormone-releasing hormone (LHRH) agonist / ovarian ablation or postmenopausal status
- Age ≥18 years
- Measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] or bone-only disease
- Patients scheduled for palliative treatment with an combination partner for first- or later-line
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate organ and marrow function
- Resolution of all acute toxic effects of prior therapy, including radiotherapy Grade <1 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures
- Fluent in spoken and written German
Exclusion Criteria:
- Prior treatment with any CDK4/6 inhibitor
- Prior adjuvant therapy with the respective endocrine combination partner if last intake <12 months prior to entering the study
- Prior palliative therapy with the respective endocrine combination partner
- More than one prior palliative chemotherapy
- 5. Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant or any of their excipients
- Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 (refer to Appendix 15.4)
- Current use of preparations containing St. John's Wort
- Participation in other studies involving investigational drug(s) (Phases I-IV) within 2 weeks before the current study treatment begins
- QTc > 480 msec on the screening ECG (using the QTcF formula and/or the QTcB (Bazett) formula); history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes
- High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment
- Patients with advanced symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement)
- Diagnosis of any second malignancy within the last 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- Known, not-irradiated CNS metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Palbociclib+AI or Fulvestrant
Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
|
Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days. Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons
Other Names:
Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
Other Names:
Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
Other Names:
Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
Other Names:
Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate (CBR)
Time Frame: 24 weeks after first administration of Palbociclib in combination with AI / fulvestrant
|
CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.
|
24 weeks after first administration of Palbociclib in combination with AI / fulvestrant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Adverse Events as assessed by CTCAE V4.0
Time Frame: From Date of Signed informed consent until PD, assessed up to 60 months.
|
Adverse Events as characterized by type, frequency, severity (as graded by National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v.4.03), and seriousness
|
From Date of Signed informed consent until PD, assessed up to 60 months.
|
Clinical Benefit Rate (CBR)
Time Frame: 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant
|
CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.
|
48 weeks after first administration of Palbociclib in combination with AI / fulvestrant
|
Progression-free Survival rate
Time Frame: At 48 weeks (all patients) and 2 years (first-line patients only) after first administration of Palbociclib in combination with AI / fulvestrant
|
Follow up 4 years after LPI
|
At 48 weeks (all patients) and 2 years (first-line patients only) after first administration of Palbociclib in combination with AI / fulvestrant
|
Overall Survival rate
Time Frame: At 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant and yearly until EOS, assessed up to 60 months.
|
Follow up 4 years after LPI
|
At 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant and yearly until EOS, assessed up to 60 months.
|
Time on treatment
Time Frame: From day of first treatment until permanent discontinuation (EOT), assessed up to 60 months.
|
Study treatment will be continued until disease progression, intolerable toxicity, death or any other reason.
|
From day of first treatment until permanent discontinuation (EOT), assessed up to 60 months.
|
Dosage
Time Frame: From day of first treatment until EOT, assessed up to 60 months.
|
|
From day of first treatment until EOT, assessed up to 60 months.
|
Adminstration schedule
Time Frame: From day of first treatment until EOT, assessed up to 60 months.
|
- dates of administration
|
From day of first treatment until EOT, assessed up to 60 months.
|
Health-related quality of life (QoL)
Time Frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Health-related QoL will be assessed with the FACT-B (Functional Assessment of Cancer Therapy-Breast) questionnaire
|
From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Health-related fatigue
Time Frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Fatigue will be assessed with the BFI (Brief Fatigue Inventory) questionnaire
|
From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Health-related anxiety and depression
Time Frame: From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Depression and anxiety will be assessed with the HADS-D (Hospital Anxiety and Depression Scale) questionnaire
|
From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.
|
Physician's assessment of patient's overall health status and change in health status compared to previous visit
Time Frame: From Screening until disease progression or start of next anti-cancer therapy, assessed up to 60 months.
|
Assessed by 2 items at each cycle/at scheduled patient visit
|
From Screening until disease progression or start of next anti-cancer therapy, assessed up to 60 months.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Letrozole
- Fulvestrant
- Palbociclib
- Anastrozole
- Exemestane
Other Study ID Numbers
- iOM-04318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Palbociclib
-
PfizerCompleted
-
PfizerCompleted
-
MegalabsNot yet recruiting
-
PfizerCompletedHealthyUnited States
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedSarcoma | LiposarcomaUnited States
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
PfizerCompleted
-
PfizerCompleted